As a single agent or in combination for: • The first line treatment of stage 3 or 4 non small cell lung cancer. • The treatment of advanced breast cancer stage 3 and 4 relapsing after or refractory to an anthracycline containing regimen.
As a single agent or in combination for: • The first line treatment of stage 3 or 4 non-small cell lung cancer. • The treatment of advanced breast cancer stage 3 and 4 relapsing after or refractory to an anthracycline containing regimen.
AMAG Pharmaceuticals announced that the FDA has approved its application to broaden the existing label for Feraheme (ferumoxytol injection) beyond...